Cargando…
Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
BACKGROUND: Mucopolysaccharidosis IVA (MPS IVA), or Morquio A syndrome, is a rare inherited metabolic disorder caused by deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase. A progressive systemic skeletal chondrodysplasia, leading to significant morbidity and reduced life expectanc...
Autores principales: | Magner, Martin, Almássy, Zsuzsanna, Gucev, Zoran, Kieć-Wilk, Beata, Plaiasu, Vasilica, Tylki-Szymańska, Anna, Zafeiriou, Dimitrios, Zaganas, Ioannis, Lampe, Christina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092811/ https://www.ncbi.nlm.nih.gov/pubmed/35538504 http://dx.doi.org/10.1186/s13023-022-02332-7 |
Ejemplares similares
-
The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers
por: Tylki-Szymańska, Anna, et al.
Publicado: (2022) -
Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement
por: Stevens, Bob, et al.
Publicado: (2021) -
Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta
por: Mueller, Brigitte, et al.
Publicado: (2018) -
Italian national consensus statement on management and pharmacological treatment of phenylketonuria
por: Burlina, Alberto, et al.
Publicado: (2021) -
Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III
por: Ghosh, Arunabha, et al.
Publicado: (2017)